Search Results

Your search for Tony Mok, MD, and Alice Shaw, MD, PhD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / 2017 ASCO Annual Meeting

Alice Tsang Shaw, MD, PhD, and Tony Mok, MD, on NSCLC: Results From the ALEX and ARCHER 1050 Trials

Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital, and Tony Mok, MD, of the Chinese University of Hong Kong, discuss their two ASCO-featured abstracts on non–small cell lung cancer: alectinib vs crizotinib in treatment-naive advanced ALK+ disease, and dacomitinib vs gefitinib for...

lung cancer

By Tony Mok, MD, and Alice Shaw, MD, PhD / 2015 European Cancer Congress

Tony Mok, MD, and Alice Shaw, MD, PhD: Expert Perspectives on ALK Inhibition and Brigatinib

Tony Mok, MD, of The Chinese University of Hong Kong, and Alice Shaw, MD, PhD, of Massachusetts General Hospital, discuss the current status and future outlook of ALK inhibition, and an assessment of brigatinib CNS activity in patients with ALK-positive non-small cell lung cancer and intracranial...

Apr

Today In Oncology

Search Results

Your search for Tony Mok, MD, and Alice Shaw, MD, PhD matches 2 pages

Alice Tsang Shaw, MD, PhD, and Tony Mok, MD, on NSCLC: Results From the ALEX and ARCHER 1050 Trials

Tony Mok, MD, and Alice Shaw, MD, PhD: Expert Perspectives on ALK Inhibition and Brigatinib

Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer

Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Improving Early Detection of Pancreatic Cancer in High-Risk Patients

Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities